Adma Biologics (ADMA) closed at $10.48 on November 4, 2026, down 5.7% from the previous close, on volume of 11,277,199 shares (30-day average 2,805,651).
Data as of November 4, 2026.
4-Nov-2026
Canaccord Genuity Keeps Their Buy Rating on ADMA Biologics (ADMA)
TipRanks (Thu, 5-Nov 7:28 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 5-Nov 7:25 AM ET)
Market Chameleon (Thu, 5-Nov 2:08 AM ET)
ADMA Biologics GAAP EPS of $0.22 beats by $0.02, revenue of $141.1M beats by $2.98M
Seeking Alpha News (Wed, 4-Nov 4:26 PM ET)
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 4-Nov 10:00 AM ET)
ADMA Biologics Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 5:35 PM ET)
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 28-Oct 7:00 AM ET)
Market Chameleon (Thu, 15-Oct 5:49 AM ET)
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of November 4, 2026, ADMA stock price declined to $10.48 with 11,277,199 million shares trading.
ADMA has a beta of 1.66, meaning it tends to be more sensitive to market movements. ADMA has a correlation of 0.10 to the broad based SPY ETF.
ADMA has a market cap of $2.35 billion. This is considered a Mid Cap stock.
Last quarter Adma Biologics reported $124 million in Revenue and $.16 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, ADMA traded as high as $25.67 and as low as $3.54.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): IJR, FBT, IWM, VTI, XBI.
ADMA has underperformed the market in the last year with a price return of -28.4% while the SPY ETF gained +14.7%. However, in the short term, ADMA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.6% vs -0.3% return in SPY. But in the last 2 weeks, ADMA shares have been beat by the market, returning -4.8% compared to an SPY return of -0.8%.
ADMA support price is $10.84 and resistance is $11.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA shares will trade within this expected range on the day.